💥 LDCT-based lung cancer screening and small cell lung cancer: Limited but non-negligible impact on #survival. A brief report
journals.sagepub.com/doi/full/10....
#LCSM #lungcancer
bsky.app/profile/lung...
The first Lung Cancer Europe Conference is underway in Vienna. Our President has just delivered her Annual Report to members.
“We’re in the most exciting period #lungcancer has ever seen. But breakthroughs only matter if people can reach them. Right now, too many people across Europe can’t.” #LCSM
Promising results for stage III lung cancer: The AFT 46/CHIO3 trial study show combining immunotherapy and chemotherapy before surgery improves outcomes for against with locally advanced non-small cell lung cancer. Dana-Farber Cancer Institute #LCSM https://bit.ly/AFT46
Emma & Jade are representing us at @lungcancereurope.bsky.social’s Conference in Vienna.
There’s a strong line up of speakers across 3 days. We’re looking forward to hearing the key takeaways they bring back, & how this can help our work for people affected by ALK+ #lungcancer in the UK. #LCSM
🆕 research in Nature suggests cancer cells can learn to resist therapy, not by mutating, but by reprogramming themselves.
In #lungcancer, resistance to targeted treatments is a big challenge. Understanding more is an important step in the search for better treatment.
doi.org/10.1038/s415... #LCSM
A big day for #lungcancer. Our FAST-NGS pilot moves forward in Greece. 🔬
Last week our team visited Metaxa Anticancer Hospital of Piraeus alongside Thermo Fisher Scientific and ANTISEL to discuss the next steps for faster biomarker testing.
www.lungcancereuropenews.eu/news/fast-ng... #LCSM
"Lung-MAP is the most transformative & pivotal trial in the MET Crusaders right now."
Hear MET Crusaders Chair Marcia K. Horn, JD, on 3 Lung-MAP studies for patients with advanced non-small cell #lungcancer with MET biomarkers. #lcsm #ClinicalTrials @focr.bsky.social
www.youtube.com/watch?v=H1mx...
A blood test is detecting combined small cell #lungcancer (cSCLC) at 3x the rate of standard biopsy.
cSCLC is rarer & deadlier than standard SCLC - a mix of 2 cancer types in 1 tumour. ~14% of patients labelled as standard SCLC have it & are being treated wrong.
www.cell.com/cell-reports... #LCSM
#Lungcancer spreads to the brain more than almost any other cancer.
For many people living with it, that’s one of the most feared complications & until recently, one of the least understood.
A 🆕 review just published in Science Signaling sets out what science is now beginning to understand. #LCSM
Have burning questions about lung cancer and the broader oncology field? Drop them in the comments, and @balazshalmos.bsky.social will answer them in OncLive's new #AskMeAnything series! 👀
NOTHING is off the table! 🔬
Comment by April 16th! ‼️
#lcsm #oncology #cancer
In just 10 days, our member organisations will be gathering in Vienna for the 1st ever #LungCancer Europe Conference.
We have an incredible programme with some truly outstanding speakers joining us from across Europe.
Join the countdown on our WhatsApp channel whatsapp.com/channel/0029... #LCSM
Lung cancer screening may have unexpected benefits beyond #lungcancer.
🆕 study tracked 26K+ people through screening rounds. Those whose scans flagged something unexpected were nearly 2X as likely to be diagnosed with a different cancer that year. #LCSM
www.lungcancereuropenews.eu/news/lung-ca...
A poster presented at the 2026 NCCN Annual Conference reported that patients with resectable #NSCLC undergoing neoadjuvant chemoimmunotherapy may have worse overall survival if they have low preoperative hemoglobin levels.
https://bit.ly/4vhE8CZ
#LungCancer #LCSM
Melissa Crouse ran out of time on April 6. She was a 20 year survivor of Stage IV Lung Cancer. Melissa was a mother, grandmother, fierce advocate, friend and beacon of hope. See you on the other side. 💔 #lcsm
Shared with thanks and respect from our colleagues at the Lung Cancer Policy Network:
LDCT screening for lung cancer enables earlier diagnosis and better outcomes. Could it also detect other diseases with similar risk factors? More: t.co/SmQndTgTF7
#LCSM #lungcancer
Welcome to the #AYACSM (Adolescent and Young Adult Cancer Societal Movement) #SkyChat! This year we are celebrating 12 YEARS OF #AYACSM CHATS!!
#BTSM #BCSM #LCSM #YACancer #AYACancer #AYAware
A new @cellpress.bsky.social perspective looks at why more cancers are being diagnosed in younger adults.
For #lungcancer, it adds to wider thinking that risk may be shaped across life by environment, inflammation and timing of exposure. #LCSM
www.cell.com/cell/fulltex...
In this UK NHS #LungCancer trial, AI cut chest X-ray reporting time, but not time to CT, diagnosis or treatment. Faster reporting alone does not fix a slow lung cancer pathway. The hold-up comes in what happens after the X-ray. #LCSM
ascoai.org/articles/202...
A new peer reviewed paper has added weight to concerns about vaping and cancer risk. It says nicotine-based e-cigarettes are likely to be carcinogenic, with likely links to #lungcancer and oral cancer.
Find out what the evidence now says 👉 www.lungcancereuropenews.eu/news/can-vap...
#LCSM
We’re delighted to announce Dr Tom Newsom-Davis as keynote speaker at our 5th ALK+ UK National Conference. 💙
Join us in London 25–27 Sept for a weekend of expert talks, trusted information & time to connect with others in the ALK+ #LungCancer community #LCSM
www.alkpositive.org.uk/national-con...
A positive EMA recommendation for tarlatamab marks an important step for relapsed extensive-stage SCLC in Europe. For people facing a disease with limited options after relapse, this matters. Now the focus must also be on fair & timely access. #LCSM
www.lungcancereuropenews.eu/news/ema-rec...
A study shows that an AI pathology tool predicts whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy. @roswellpark.bsky.social #lcsm #oncology
www.onclive.com/view/new-ai-...
Lurbinectedin plus atezolizumab received CHMP recommendation as first-line maintenance for ES-SCLC that has not progressed following induction therapy.
#oncology #lcsm #SCLC
www.onclive.com/view/chmp-re...
ELCC is always an important meeting for us, but this year felt esp significant. For the 1st time, we launched our annual #LungCancer report during ELCC - a big change for us, & it felt like the right move.
It was also chance to introduce some of our new team & spend time with supporters. #LCSM
New March 2026 data from Cancer Research UK shows #lungcancer death rates in the UK have fallen by 22% over the past decade.
But the picture is very different for men and women. Over the last decade, lung cancer incidence rates rose by 8% in women, while falling by 13% in men.
#LCSM
A 🆕 article in Lung Cancer adds more detail from the ALINA trial, showing that adjuvant alectinib continued to show disease-free survival benefit over chemo across surgical subgroups in resected early-stage ALK+ #LungCancer. ALINA isn’t new, but this gives a closer look at who benefited. #LCSM
WATCH: Fred R. Hirsch, MD, PhD, of @mountsinainyc.bsky.social discusses research validating an AI-assisted PD-L1 scoring algorithm against original Blueprint study data in lung cancer. #ELCC26 #lcsm #lungcancer #AI
www.onclive.com/view/dr-hirs...
WATCH: Nicolas Girard, MD, PhD, of @institutcurie.bsky.social discusses updated data from the phase 2 PALOMA-2 trial that were presented at the 2026 European Lung Cancer Congress. #ELCC26 #ELCC2026 #lcsm #lungcancer
www.onclive.com/view/dr-gira...
